J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Sorafenib plus 5-azacytidine (AZA) in older untreated FLT3-ITD mutated AML.
Maro Ohanian,Guillermo Garcia-Manero,Mark J. Levis,Elias Jabbour,Naval Daver,Gautam Borthakur,Tapan M. Kadia,Mark Brandt,Sherry Pierce,Jan A. Burger,Mary Ann Richie,Keyur P. Patel,Jorge E. Cortes,Hagop M. Kantarjian,Farhad Ravandi +14 more
TL;DR: Sorafenib plus 5-azacytidine (AZA) is observed to be safe and effective in relapsed / refractory FLT3-ITD mutated acute myeloid leukemia (AML) patients.
Journal ArticleDOI
Targeting microenvironment-mediated resistance in leukemias: Phase I trial of mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor/g-CSF/sorafenib.
Michael Andreeff,Zhihong Zeng,Mary A. Kelly,Rui-Yu Wang,Teresa McQueen,Seshagiri Duvvuri,Gul Nowshad,Gautam Borthakur,Jan A. Burger,Tapan M. Kadia,Elias Jabbour,Jorge E. Cortes,Hagop M. Kantarjian,Marina Konopleva +13 more
TL;DR: First data testing this concept in patients with R/R FLT3-ITD AML is reported, with an overall response rate of 6/10 and increased in vivo activity of S combined with CXCR4 inhibitor Plerixafor (P) and G-CSF (G).
Journal ArticleDOI
Integrating New Therapies for Chronic Lymphocytic Leukemia.
TL;DR: The most active targeted treatments for CLL patients are the kinase inhibitors, which inhibit signaling of surface receptors, especially the B-cell antigen receptor, and the BCL-2 antagonist venetoclax as discussed by the authors.
Journal ArticleDOI
A patient-reported outcome measure for symptoms of AML/MDS.
Loretta A. Williams,Araceli Garcia-Gonzalez,Hycienth Ahaneku,Jorge E. Cortes,Guillermo Garcia-Manero,Hagop M. Kantarjian,Qiuling Shi,Gautam Borthakur,Jan A. Burger,Elias Jabbour,Koichi Takahashi,H. Lin,Achala Limaye,Charles S. Cleeland +13 more
TL;DR: The aim is to develop a short, valid, reliable patient-reported outcome measure of AML and MDS symptoms for research and practice.
Journal ArticleDOI
A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Nicholas J. Short,Hagop M. Kantarjian,Farhad Ravandi,Xuelin Huang,Nitin Jain,Naval Daver,Deborah A. Thomas,Naveen Pemmaraju,Rita Khouri,Joseph D. Khoury,Jeffrey L. Jorgensen,Yesid Alvarado,Koji Sasaki,Marina Konopleva,Guillermo Garcia-Manero,Tapan M. Kadia,Jorge E. Cortes,Christopher B. Benton,Gautam Borthakur,Jan A. Burger,Maro Ohanian,William G. Wierda,Zeev Estrov,Steven M. Kornblau,Courtney D. DiNardo,Alessandra Ferrajoli,Jovitta Jacob,Ameena Manzoor,Rebecca Garris,Susan O'Brien,Elias Jabbour +30 more
TL;DR: The addition of INO to low-intensity chemotherapy might improve outcomes in older pts with newly diagnosed ALL, and MRD negativity by 6-color flow cytometry was achieved in 36/46 pts after 1 cycle and 49/51 pts overall.